Bunker Hill Capital, a leading Boston based private equity investor in lower middle market companies, announced that it has made a growth equity investment in Courtagen Life Sciences, Inc. Headquartered in Woburn, MA, Courtagen is a diagnostic testing services business founded in 2009 by Brian and Brendan McKernan, who currently serve as CEO and President, respectively. The current funding round will accelerate the expansion of Courtagen’s commercial operations, including expanding sales and marketing and laboratory capacity while also providing working capital to meet the growing needs of the business. Courtagen is a privately held life sciences and molecular information company that converts genomic data into actionable clinical information for the diagnosis of critical pediatric neurological and metabolic disorders. Specifically, Courtagen focuses on mitochondrial disorders, epilepsy, and intellectual disability, including autism spectrum disorders. Courtagen’s state-of-the art Next Generation Sequencing clinical laboratory integrates cloud-based computing and custom analytical methods to provide the most comprehensive genetic information to clinicians, patients, and their families to help diagnose diseases and guide treatment decisions.